Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
18 results
D1.116 - Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis
D1.117 - Combing dual biologics therapy for severe asthma : a series of ten cases
D1.118 - The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience
D1.119 - Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model
D1.123 - Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment
D1.124 - Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab
D1.125 - Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos
D1.129 - Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD
D1.131 - TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)
D3.364 - Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema
D3.358 - The impact of limited access to On-Demand Treatment for Hereditary Angioedema on Quality of life: a comparison between two income settings
D3.359 - Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment
D3.362 - Use and safety of canakinumab during pregnancy
D3.363 - Vitamin D3 deficiency promotes epithelial-to-mesenchymal transition and thus favours pulmonary fibrosis development in the murine model of hypersensitivity pneumonitis
D3.365 - The role of anosmia in predicting biologic responsiveness for Chronic Rhinosinusitis with Nasal Polyposis
D3.366 - Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria
D3.367 - Mental health, sexual functionality, quality of life, and patient experiences with chronic rhinosinusitis with nasal polyps at UNIMEQ-ORL in Bogotá, Colombia, 2022-2024: a mixed-methods study
D3.368 - Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year
Download the app
The congress at your fingertips
Available on
Download